IRADIMED Reports Record Q4 & Full Year 2025 Results, Raises Dividend, and Provides Strong 2026 Guidance

summarizeSummary

IRADIMED CORP reported record revenue and EPS for Q4 and full year 2025, increased its quarterly cash dividend, and provided optimistic financial guidance for 2026, driven by a new product rollout.

check_boxKey Events

• Record Q4 and Full Year 2025 Financial Results

  The company reported record revenue of $22.7 million for Q4 2025 (up 17% YoY) and $83.8 million for full year 2025 (up 14% YoY). GAAP diluted EPS reached $0.50 for Q4 (up 25% YoY) and $1.75 for the full year (up 17% YoY).

• Increased Quarterly Cash Dividend

  IRADIMED CORP increased its regular quarterly cash dividend to $0.20 per share from $0.17 per share, payable on March 6, 2026.

• Provided 2026 Financial Guidance

  For Q1 2026, the company expects revenue between $21.0 million and $22.0 million, with GAAP diluted EPS of $0.39 to $0.43. Full year 2026 guidance projects revenue of $91.0 million to $96.0 million and GAAP diluted EPS of $1.90 to $2.05.

• Next-Generation Product Rollout Underway

  The initial 3870 units of the next-generation MRI-compatible IV infusion pump were successfully shipped in Q4 2025, with a full rollout expected in Q1 2026 and meaningful revenue contribution in the second half of the year.

auto_awesomeAnalysis

IRADIMED CORP announced robust financial performance for both the fourth quarter and full year of 2025, achieving record revenue and diluted EPS. The company's decision to increase its regular quarterly cash dividend signals strong confidence in its ongoing business outlook and financial health. Furthermore, the successful initial shipment of its next-generation 3870 MRI-compatible IV infusion pump and its anticipated full rollout in 2026 indicate future growth drivers. The provided financial guidance for Q1 and full year 2026 offers investors a clear outlook on expected performance.